NO2964264T3 - - Google Patents
Info
- Publication number
- NO2964264T3 NO2964264T3 NO14709884A NO14709884A NO2964264T3 NO 2964264 T3 NO2964264 T3 NO 2964264T3 NO 14709884 A NO14709884 A NO 14709884A NO 14709884 A NO14709884 A NO 14709884A NO 2964264 T3 NO2964264 T3 NO 2964264T3
- Authority
- NO
- Norway
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
- A61K47/6831—Fungal toxins, e.g. alpha sarcine, mitogillin, zinniol or restrictocin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Toxicology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Gastroenterology & Hepatology (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13001074.7A EP2774624A1 (fr) | 2013-03-04 | 2013-03-04 | Dérivés d'amatoxine |
| EP14709884.2A EP2964264B1 (fr) | 2013-03-04 | 2014-03-10 | Dérivés d'amatoxine |
| PCT/EP2014/000614 WO2014135282A1 (fr) | 2013-03-04 | 2014-03-10 | Dérivés d'amatoxine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO2964264T3 true NO2964264T3 (fr) | 2018-02-10 |
Family
ID=47826817
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO14709884A NO2964264T3 (fr) | 2013-03-04 | 2014-03-10 |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US9982018B2 (fr) |
| EP (2) | EP2774624A1 (fr) |
| KR (1) | KR20160006162A (fr) |
| AR (1) | AR095019A1 (fr) |
| AU (1) | AU2014224928B2 (fr) |
| BR (1) | BR112015021838B1 (fr) |
| CA (1) | CA2903614C (fr) |
| DK (1) | DK2964264T3 (fr) |
| ES (1) | ES2652182T3 (fr) |
| HK (2) | HK1200312A1 (fr) |
| IL (1) | IL240863B (fr) |
| MX (1) | MX366503B (fr) |
| NO (1) | NO2964264T3 (fr) |
| NZ (1) | NZ710729A (fr) |
| RU (1) | RU2695370C2 (fr) |
| SG (1) | SG11201507089PA (fr) |
| TW (1) | TW201441248A (fr) |
| UA (1) | UA117364C2 (fr) |
| WO (1) | WO2014135282A1 (fr) |
| ZA (1) | ZA201505790B (fr) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10077318B2 (en) | 2014-09-12 | 2018-09-18 | Genentech, Inc. | Cysteine engineered antibodies and conjugates |
| EP3191520B1 (fr) | 2014-09-12 | 2020-01-01 | Genentech, Inc. | Anticorps anti-cll-1 et immunoconjugués |
| SG10201809668TA (en) | 2014-09-12 | 2018-11-29 | Genentech Inc | Anti-her2 antibodies and immunoconjugates |
| US9938323B2 (en) | 2014-11-06 | 2018-04-10 | Novartis Ag | Amatoxin derivatives and conjugates thereof as inhibitors of RNA polymerase |
| MX2017011298A (es) * | 2015-03-04 | 2018-06-19 | Univ Texas | Métodos para tratar cáncer que albergan la pérdida hemicigota de tp53. |
| EP3268047B9 (fr) * | 2015-03-09 | 2024-01-10 | Heidelberg Pharma Research GmbH | Conjugués amatoxine-anticorps |
| JP6632118B2 (ja) * | 2015-09-04 | 2020-01-15 | 学校法人 岩手医科大学 | 腫瘍の再発を抑制する医薬 |
| MA43354A (fr) | 2015-10-16 | 2018-08-22 | Genentech Inc | Conjugués médicamenteux à pont disulfure encombré |
| EP3452492A1 (fr) | 2016-05-05 | 2019-03-13 | Novartis AG | Dérivés d'amatoxine et leurs conjugués à utiliser en tant qu'inhibiteurs de l'arn polymérase |
| US20170370906A1 (en) | 2016-05-27 | 2017-12-28 | Genentech, Inc. | Bioanalytical analysis of site-specific antibody drug conjugates |
| US20190328901A1 (en) | 2016-06-17 | 2019-10-31 | Magenta Therapeutics, Inc. | Compositions and methods for the depletion of cells |
| SG11201811290VA (en) | 2016-06-17 | 2019-01-30 | Magenta Therapeutics Inc | Compositions and methods for the depletion of cd117+cells |
| CN109963871A (zh) | 2016-08-05 | 2019-07-02 | 豪夫迈·罗氏有限公司 | 具有激动活性的多价及多表位抗体以及使用方法 |
| WO2018115466A1 (fr) | 2016-12-23 | 2018-06-28 | Heidelberg Pharma Research Gmbh | Conjugués d'anticorps à base d'amanitine |
| SG10202102897PA (en) | 2017-01-20 | 2021-04-29 | Magenta Therapeutics Inc | Compositions and methods for the depletion of cd137+ cells |
| WO2019034175A1 (fr) * | 2017-08-18 | 2019-02-21 | 四川百利药业有限责任公司 | Conjugué d'anticorps de type amatoxine non-naturelle |
| AU2018354189A1 (en) | 2017-10-24 | 2020-04-23 | Crispr Therapeutics Ag | Compositions and methods for the depletion of CD117+ cells |
| JP7280254B2 (ja) | 2017-10-24 | 2023-05-23 | マジェンタ セラピューティクス インコーポレイテッド | Ｃｄ１１７＋細胞を減少させるための組成物及び方法 |
| WO2019197654A1 (fr) * | 2018-04-13 | 2019-10-17 | Heidelberg Pharma Research Gmbh | Conjugué d'amatoxine ciblé pour le traitement de tumeurs solides |
| AU2019311077A1 (en) | 2018-07-23 | 2021-02-25 | Heidelberg Pharma Research Gmbh | Use of anti-CD5 antibody drug conjugate (ADC) in allogeneic cell therapy |
| MX2021012961A (es) | 2019-04-24 | 2021-11-25 | Heidelberg Pharma Res Gmbh | Conjugados de anticuerpo y farmaco de amatoxina y usos de los mismos. |
| CA3138405A1 (fr) | 2019-05-23 | 2020-11-26 | Heidelberg Pharma Research Gmbh | Conjugues anticorps-medicament pourvus de lieurs clivables |
| KR102092817B1 (ko) * | 2019-08-22 | 2020-03-24 | 한국화학연구원 | 아마톡신 유도체 및 이의 제조방법 |
| CN111308100B (zh) * | 2020-04-13 | 2023-04-21 | 北京维德维康生物技术有限公司 | 一种检测β-鹅膏毒肽的酶联免疫试剂盒及其制备和应用 |
| KR20230069211A (ko) | 2020-09-18 | 2023-05-18 | 아라리스 바이오테크 아게 | 아미노산-기반 링커를 사용한 트란스글루타미나제 접합 방법 |
| CA3196218A1 (fr) | 2020-10-25 | 2022-04-28 | Philipp SPYCHER | Moyens et procedes de fabrication de conjugues anticorps-lieur |
| AR125130A1 (es) * | 2021-03-19 | 2023-06-14 | Heidelberg Pharma Res Gmbh | Conjugados de amatoxina y anticuerpo específicos de linfocitos b |
| WO2023072934A1 (fr) | 2021-10-25 | 2023-05-04 | Araris Biotech Ag | Procédés de production de conjugués anticorps-lieur |
| WO2023161291A1 (fr) | 2022-02-22 | 2023-08-31 | Araris Biotech Ag | Liaisons peptidiques comprenant deux ou plusieurs charges utiles |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU633698B2 (en) | 1990-01-12 | 1993-02-04 | Amgen Fremont Inc. | Generation of xenogeneic antibodies |
| EP2015782A4 (fr) * | 2006-04-12 | 2010-04-07 | Crosslink Genetics Corp | Compositions et procédés permettant de moduler l'expression des gènes |
| EP1859811B1 (fr) | 2006-05-27 | 2011-08-24 | Faulstich, Heinz, Dr. | Application de conjuguées d' amatoxines et de phallotoxines avec des macromolécules pour la thérapie du cancer et de l'Inflammation |
| KR20110140124A (ko) | 2009-04-08 | 2011-12-30 | 하인즈 파울스티히 | 암치료용 아미톡신-활성 표적 결합 부위 |
| LT3192529T (lt) * | 2009-04-08 | 2020-06-25 | Faulstich, Heinz, Dr. | Amatoksinu užtaisyti terapiniai su ląstelės paviršiumi susirišantys komponentai, sukonstruoti navikų terapijai |
| EP2436398B1 (fr) * | 2010-09-30 | 2013-01-23 | Heidelberg Pharma GmbH | Conjugués d'amatoxine avec liens améliorés |
| EP2497499A1 (fr) * | 2011-03-10 | 2012-09-12 | Heidelberg Pharma GmbH | Conjugués d'amatoxine avec liens améliorés |
-
2013
- 2013-03-04 EP EP13001074.7A patent/EP2774624A1/fr not_active Withdrawn
-
2014
- 2014-03-04 TW TW103107305A patent/TW201441248A/zh unknown
- 2014-03-05 AR ARP140100717A patent/AR095019A1/es unknown
- 2014-03-10 RU RU2015142093A patent/RU2695370C2/ru active
- 2014-03-10 EP EP14709884.2A patent/EP2964264B1/fr active Active
- 2014-03-10 CA CA2903614A patent/CA2903614C/fr active Active
- 2014-03-10 DK DK14709884.2T patent/DK2964264T3/en active
- 2014-03-10 KR KR1020157027378A patent/KR20160006162A/ko not_active Application Discontinuation
- 2014-03-10 WO PCT/EP2014/000614 patent/WO2014135282A1/fr active Application Filing
- 2014-03-10 SG SG11201507089PA patent/SG11201507089PA/en unknown
- 2014-03-10 AU AU2014224928A patent/AU2014224928B2/en active Active
- 2014-03-10 NZ NZ710729A patent/NZ710729A/en unknown
- 2014-03-10 ES ES14709884.2T patent/ES2652182T3/es active Active
- 2014-03-10 MX MX2015011583A patent/MX366503B/es active IP Right Grant
- 2014-03-10 NO NO14709884A patent/NO2964264T3/no unknown
- 2014-03-10 US US14/769,970 patent/US9982018B2/en active Active
- 2014-03-10 BR BR112015021838-5A patent/BR112015021838B1/pt active IP Right Grant
- 2014-10-03 UA UAA201509530A patent/UA117364C2/uk unknown
- 2014-12-24 HK HK14113008.7A patent/HK1200312A1/xx unknown
-
2015
- 2015-08-12 ZA ZA2015/05790A patent/ZA201505790B/en unknown
- 2015-08-26 IL IL240863A patent/IL240863B/en active IP Right Grant
-
2016
- 2016-04-01 HK HK16103769.5A patent/HK1215795A1/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2903614A1 (fr) | 2014-09-12 |
| NZ710729A (en) | 2019-05-31 |
| BR112015021838A2 (pt) | 2017-07-18 |
| IL240863A0 (en) | 2015-10-29 |
| BR112015021838B1 (pt) | 2021-12-28 |
| KR20160006162A (ko) | 2016-01-18 |
| MX366503B (es) | 2019-07-11 |
| WO2014135282A8 (fr) | 2015-09-17 |
| AU2014224928B2 (en) | 2017-10-19 |
| CA2903614C (fr) | 2021-07-06 |
| RU2015142093A (ru) | 2017-04-07 |
| AR095019A1 (es) | 2015-09-16 |
| TW201441248A (zh) | 2014-11-01 |
| EP2774624A1 (fr) | 2014-09-10 |
| US20160002298A1 (en) | 2016-01-07 |
| SG11201507089PA (en) | 2015-10-29 |
| ZA201505790B (en) | 2017-11-29 |
| MX2015011583A (es) | 2016-07-29 |
| UA117364C2 (uk) | 2018-07-25 |
| EP2964264A1 (fr) | 2016-01-13 |
| WO2014135282A1 (fr) | 2014-09-12 |
| AU2014224928A1 (en) | 2015-09-10 |
| HK1200312A1 (en) | 2015-08-07 |
| US9982018B2 (en) | 2018-05-29 |
| ES2652182T3 (es) | 2018-01-31 |
| DK2964264T3 (en) | 2017-12-11 |
| EP2964264B1 (fr) | 2017-09-13 |
| HK1215795A1 (zh) | 2016-09-15 |
| RU2695370C2 (ru) | 2019-07-23 |
| IL240863B (en) | 2019-02-28 |